GlassScriptPhysician profile
Michael J Prematta
NPI 1801009444
$167,880.78
in general payments reported to CMS, 2019-2025
47 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $12K · 2021: $54K · 2022: $16K · 2023: $32K · 2024: $12K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Food and Beverage: $13K · Consulting Fee: $3,598 · Travel and Lodging: $2,006 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,557.00 |
| Food and Beverage | $12,899.23 |
| Consulting Fee | $3,598.00 |
| Travel and Lodging | $2,005.67 |
| Education | $158.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $69,511.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $43,215.68 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $26,187.87 | 2019-2025 | |
| Genentech USA, INC. | $9,804.14 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,758.71 | 2019-2024 | Spiriva Respimat, Spiriva |
| Regeneron Healthcare Solutions, INC. | $2,262.33 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,486.87 | 2019-2025 | |
| Csl Behring | $1,034.69 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $872.18 | 2019-2025 | |
| Pfizer INC. | $740.89 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $653.75 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $616.24 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Takeda Pharmaceuticals U.S.A., INC. | $535.90 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Grifols USA, LLC | $427.83 | 2019-2025 | Xembify |
| Kaleo, INC. | $383.54 | 2019-2024 | Auvi-Q |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $336.20 | 2021-2025 | Tezspire |
| Incyte Corporation | $257.68 | 2021-2022 | |
| Abbvie INC. | $160.97 | 2022-2024 | |
| Pharming Healthcare, INC. | $138.06 | 2020-2024 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $113.56 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $113.54 | 2023-2025 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $105.04 | 2019-2021 | |
| Blueprint Medicines Corporation | $95.61 | 2023-2025 | Ayvakit |
| Organon LLC | $89.24 | 2025 | Vtama |
| Electromed, INC. | $76.88 | 2024-2025 | Smartvest |
| Philips North America LLC | $71.78 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $65.46 | 2019-2023 | |
| Bio Products Laboratory USA, INC. | $60.99 | 2019-2023 | Coagadex, Gammaplex |
| Covis Pharma Gmbh | $60.01 | 2022-2023 | |
| Ionis Pharmaceuticals, INC. | $52.56 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $49.48 | 2021 | |
| Insmed, INC. | $49.08 | 2025 | Brinsupri, Arikayce |
| Octapharma USA, INC. | $47.92 | 2019-2024 | Cutaquig |
| Eyevance Pharmaceuticals LLC | $43.54 | 2021 | |
| Greer Laboratories, INC. | $43.27 | 2025 | Oralair |
| Horizon Therapeutics Plc | $41.95 | 2019-2022 | |
| Leo Pharma INC. | $38.58 | 2022 | |
| Adma Biomanufacturing LLC | $36.42 | 2021-2022 | |
| Seqirus USA INC | $34.46 | 2024-2025 | Fluad, Flucelvax |
| Aytu Biopharma, INC. | $34.15 | 2022-2024 | Karbinal |
| Aimmune Therapeutics, INC. | $32.01 | 2020-2022 | |
| Shire North American Group INC | $30.31 | 2019 | |
| Galderma Laboratories, L.P. | $28.79 | 2025 | Nemluvio |
| Phathom Pharmaceuticals, INC. | $28.75 | 2024 | Voquezna |
| Gc Biopharma USA, INC. | $23.86 | 2025 | Alyglo |
| Biocryst Pharmaceuticals, INC. | $15.09 | 2020 | |
| Circassia INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Prematta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.